Celyad Announces February and March 2019 Investor Conference Schedule
MONT-SAINT-GUIBERT, Belgium, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to present at four investor conferences in February and March 2019.
Conference details:
| 8th Annual SVB Leerink Global Healthcare Conference | |
| Date: | Thursday, February 28, 2019 |
| Presentation time: | 1:30 p.m. ET |
| Location: | New York, NY |
| A live webcast of the presentation can be accessed here. | |
| Cowen 39th Annual Health Care Conference | |
| Date: | Monday, March 11, 2019 |
| Presentation Time: | 3:30 p.m. ET |
| Location: | Boston, MA |
| A live webcast of the presentation can be accessed here. | |
| BioCapital Europe 2019* | |
| Date: | Thursday, March 14, 2019 |
| Presentation Time: | 3:20 p.m. CET |
| Location: | Amsterdam |
| William Blair 9th Annual Cancer Immunotherapy Conference* | |
| Date: | Wednesday, March 20, 2019 |
| Presentation Time: | 10:30 a.m. ET |
| Location: | New York, NY |
_____________________________
* This event will not be webcast.
An archived recording of the webcasts noted above will also be available under Events & Webcasts in the Investors section of the Company’s website.
About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), is currently being evaluated in a Phase I dose escalation clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). The safety and clinical activity of the CYAD-01 therapy concurrently administered with standard-of-care treatments or preconditioning chemotherapy is also being assessed in a full clinical development program focused on acute myeloid leukemia and colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.
For more information, please contact:
|
Celyad Filippo Petti, Chief Financial Officer – investors@celyad.com Alexandrine Hazard, Corporate Communications - T: +32(0) 10 39 41 58 - Communications@celyad.com |
|
For Belgium: Comfi Laure-Eve Montfort - T.: +32 (0)2 290 90 91 – celyad@comfi.be |
|
For the U.S.: LifeSci Advisors Daniel Ferry – T.: +1 (617) 535 7746 – daniel@lifesciadvisors.com Public Relations: Sara Zelkovic – T:+1 (646) 876 4933 - sara@lifescipublicrelations.com |
